Shares of Medexus Pharmaceuticals Inc. (TSE:MDP - Get Free Report) have been given an average recommendation of "Buy" by the seven ratings firms that are covering the company, MarketBeat reports. Two equities research analysts have rated the stock with a hold rating, one has issued a buy rating and four have assigned a strong buy rating to the company. The average twelve-month price objective among brokers that have covered the stock in the last year is C$5.49.
A number of analysts recently issued reports on the stock. Raymond James upgraded shares of Medexus Pharmaceuticals from an "outperform" rating to a "strong-buy" rating and set a C$4.00 target price on the stock in a research report on Wednesday, January 8th. Stifel Canada lowered shares of Medexus Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Thursday, February 6th. Ventum Financial raised their target price on shares of Medexus Pharmaceuticals from C$5.00 to C$6.25 and gave the stock a "buy" rating in a research report on Thursday, January 30th. Alliance Global Partners upgraded shares of Medexus Pharmaceuticals to a "strong-buy" rating in a research report on Monday, December 23rd. Finally, Leede Financial upgraded shares of Medexus Pharmaceuticals from a "moderate buy" rating to a "strong-buy" rating in a research report on Wednesday, January 22nd.
Check Out Our Latest Stock Analysis on MDP
Medexus Pharmaceuticals Price Performance
Shares of MDP opened at C$2.57 on Wednesday. The firm has a 50 day simple moving average of C$3.49 and a 200-day simple moving average of C$2.91. Medexus Pharmaceuticals has a 1-year low of C$1.47 and a 1-year high of C$5.56. The stock has a market cap of C$57.54 million, a price-to-earnings ratio of 12.29 and a beta of 1.96.
Medexus Pharmaceuticals Company Profile
(
Get Free ReportMedexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medexus Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medexus Pharmaceuticals wasn't on the list.
While Medexus Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
